Market closed

Erasca/ERAS

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Erasca

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.

Ticker

ERAS
Trading on

Industry

Biotechnology

Employees

126

Erasca Metrics

BasicAdvanced
$777M
Market cap
-
P/E ratio
-$0.94
EPS
1.18
Beta
-
Dividend rate
$777M
1.18
$3.45
$1.51
2.3M
16.792
16.495
11.014
11.964
-19.14%
-38.90%
1.66
1.66
-3.433
-45.10%
-43.96%

What the Analysts think about Erasca

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Erasca stock.

Erasca Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Erasca Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy ERAS

$

Sign up or log in to buy
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Erasca stock?

Erasca (ERAS) has a market cap of $777M as of October 12, 2024.

What is the P/E ratio for Erasca stock?

The price to earnings (P/E) ratio for Erasca (ERAS) stock is 0 as of October 12, 2024.

Does Erasca stock pay dividends?

No, Erasca (ERAS) stock does not pay dividends to its shareholders as of October 12, 2024.

When is the next Erasca dividend payment date?

Erasca (ERAS) stock does not pay dividends to its shareholders.

What is the beta indicator for Erasca?

Erasca (ERAS) has a beta rating of 1.18. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.